Drugs / Kisspeptin
Kisspeptin
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04958109 | Oct 2021 → Oct 2022 | metabolic disease | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 21 trial · 1 met primary | ||||||
| Phase 2 | NCT01667406 | Jun 2012 → Oct 2016 | infertility disorder | Imperial College London | Completed | Met primary |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Kisspeptin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01667406 ↗ |
| Known as | Kiss-1 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650403 ↗ |
| Known as | Kiss-1 metastasis suppressor | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650403 ↗ |
| Known as | Metastin | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650403 ↗ |
| Action | Activate | “Kisspeptin indirectly stimulates gonadotropin secretion by acting on hypothalamic GnRH neurons.” PMID 29206944 ↗ Feb 2018 |
| Modality | Peptide | “Kisspeptin is a hypothalamic neuropeptide” PMID 29446481 ↗ Mar 2018 |
| Route | Subcutaneous | “single kisspeptin dose 1.6 nmol/kg subcutaneously” NCT01667406 ↗ |